Skip to main navigation Skip to search Skip to main content

Current LC-MS-based strategies for characterization and quantification of antibody-drug conjugates

  • Xiaoyu Zhu
  • , Shihan Huo
  • , Chao Xue
  • , Bo An
  • , Jun Qu
  • SUNY Buffalo
  • GlaxoSmithKline

Research output: Contribution to journalReview articlepeer-review

83 Scopus citations

Abstract

The past few years have witnessed enormous progresses in the development of antibody-drug conjugates (ADCs). Consequently, comprehensive analysis of ADCs in biological systems is critical in supporting discovery, development and evaluation of these agents. Liquid chromatography-mass spectrometry (LC-MS) has emerged as a promising and versatile tool for ADC analysis across a wide range of scenarios, owing to its multiplexing ability, rapid method development, as well as the capability of analyzing a variety of targets ranging from small-molecule payloads to the intact protein with a high, molecular resolution. However, despite this tremendous potential, challenges persist due to the high complexity in both the ADC molecules and the related biological systems. This review summarizes the up-to-date LC-MS-based strategies in ADC analysis and discusses the challenges and opportunities in this rapidly-evolving field.

Original languageEnglish
Pages (from-to)209-220
Number of pages12
JournalJournal of Pharmaceutical Analysis
Volume10
Issue number3
DOIs
StatePublished - Jun 2020

Keywords

  • Antibody-drug conjugate (ADC)
  • Drug-to-antibody ratio (DAR)
  • Liquid chromatography-mass spectrometry (LCMS)

Fingerprint

Dive into the research topics of 'Current LC-MS-based strategies for characterization and quantification of antibody-drug conjugates'. Together they form a unique fingerprint.

Cite this